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ABSTRACT

(

Nifedipine has been shown to be an effective and a well
tolerated

medication for the treatment of several cardiova-

scular diseases. Its low water solubility, however, leads to
poor drug absorption from oral dosage forms while commercially available soft capsules lead to a short half - life.
In this study a method was developed to prepare control led release nifedipine tablets which would release the drug
quickly and sustain the release for a longer period of time.
Solid dispersions of nifedipine with polyvinylpyrrolidone
(40T) and polyethylene glycol 8000 were prepared to enhance
dissolution and microporous polypropylene containing 75%
void space was used to control the release to a desired
level.
Various ratios of the two polymers were used.

The

results indicate that the solid dispersion technique is a
good approach to enhance the dissolution of nifedipine.
However the polypropylene polymer used as a homogeneously
dispersed matrix does not provide a zero - order release
rate in low concentrations.
A preliminary study was also carried out to measure the
rate of photodegradation of nifedipine solution in a normally lighted lab devoid of sunlight. The results obtained show
that the photodegradation of nifedipine follows first order
kinetics with a t 90 of 19 minutes. The pH of the solution in

(

the range of 4 .2 - 7 .4 did not alter this rate.
ii

The solubility of nifedipine in water was found to be

(

about 5 mg/L at 25 degrees Celcius. There was no significant
difference

between the water solubility and the solubility

in phosphate buffer (pH 7.4) or the solubility in 0.1 N HCl.

(

(
iii

(

"For the things we
have to learn before
we can do them, we
learn by doing them"
- Aristotle

iv
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I.

INTRODUCTION

(
1.

NIFEDIPINE

Nifedipine, a dihydropyridine derivative is one of a
group of compounds thought to act by blocking the transmembrane inward movement of calcium. It has been shown to be an
effective and relatively well tolerated treatment for stable, variant and unstable angina, mild to severe hypertension,

and Raynaud's phenomenon (93).
Clinical trials support the view that nifedipine can be

considered a first line choice in all grades of angina,
especially when coronary vasospasm is the underlying cause
or when hypertension and / or congestive heart failure are
added complications. Nifedipine also appears to be particularly useful in clinical situations

when a rapid lowering

of elevated blood pressure is needed, and there is growing
evidence that it is an effective and safe choice for the
long term management of patients with mild to moderate
hypertension (93).
However, the majority of data have been from medium
term studies,

and confirmation of its long term usefulness

in well designed trials is still required. Additionally,

it

has convincingly been shown to be a useful adjunct to controlling blood pressure in patients refractory to conventional treatment with beta blockers,

diuretics and various

vasodilators (12,32). Nifedipine reduces the number, duration and severity of vasospastic attacks in more than 60% of
1

patients with Raynaud's phenomenon of varying etiology,

(

and

in individual cases it apparently facilitates the healing of
digital ulcers.
Thus nifedipine is a worthwhile alternative to other
drugs available for the treatment of the various forms of
angina, acute episodes of hypertension, mild to severe hypertension (18,23,24,35,50,63,67,84,103) and Raynaud's phenomenon (22).
PHARMACOKINETICS :
Few well designed studies have been performed that
adequately describes pharmacokinetic properties of nifedipine. The paucity of information detailing the kinetic aspects of nifedipine is due primarily to two factors (93).
Firstly,

until recently no parenteral dosage form was

commercially available,
solution

and laboratory preparation of a

for intravenous pharmacokinetic studies was diff i-

cult due to

the photosensitive nature of such solutions.

Nifedipine is very light sensitive and breaks down rapidly
on exposure to daylight, tungsten bulb light, standard fluorescent light or ultraviolet irradiation to its more stable
nitroso

or

nitropyridine

(see

fig.l)

derivatives

(6,21,37,52). Nifedipine is stable, however,

when "gold"

fluorescent light is used (37).
Secondly,

there have been problems in developing a

sufficiently sensitive and specific method for analysis of
nifedipine plasma concentrations after therapeutic doses.
Although the concentrations of nifedipine in body fluids has
2
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Fig. 1. Photodecomposition and biotransformation scheme.
nifedipine;

I is

p-I and p-II are photodegradation products

and M-I and M-II are metabolites (from ref. 52).
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been determined by radioisotope (93),
quid

chromatograghy

(21,48),

(51,52,

64,74),

high performance ligas chromatography

fluorimetry (55) and mass spectrometry (40), the

various discrepancies reported for nifedipine pharmacokinetic parameters may originate in part from the inefficiency
of some of these assay techniques in distinguishing parent
from its inactive metabolites and photodegradation products
(93) .
Clinical studies have shown that the hypotensive effect
of nifedipine could be correlated with the plasma drug
concenration (4,7,55). The absorption of nifedipine, however,

is poor when administered orally in a solid dosage form

(96) because of its poor water solubility. Several studies
reported that the nif edipine plasma levels increased rapidly
after oral administration of commercially available (soft
capsule) water soluble formulations (29,78) with peak plasma
concentrations occuring after about 30 minutes of administration. With sublingual administration the peak occured
after 1 hour (78). The half - life of elimination from the
commercial capsule was only about 3.5 hours (29). Consequently,

the antihypertensive effects of nifedipine lasts only

for a few hours which restricts its use in treating chronic
hypertension (101). On the other hand Taburet et al (100)
administered a tablet formulation with crystalline form of
nifedipine to hypertensive men and found that the resulting
tmax from the tablets was about 2 hours with an elimination
half life of about 10 hours. These values did not differ

4

between doses of 20, 40, and 60 milligrams.
From these studies it is clear that in order to optimize the delivery of nifedipine a dosage form must be developed which releases the drug quickly

(i.e.

has a

high

dissolution rate) while maintaining a longer elimination
half life.

2. ENHANCEMENT OF DISSOLUTION RATE
The following section describes briefly the various
methods used for enhancing the dissolution rate of drugs in
solid dosage forms. The basis of these methods is the Noyes
- Whitney equation modified by Underwood and Cadwallader (105):
(1)
where dW/dt is the dissolution rate,

K is a dissolution

constant, S is the surface area of the solid, Csat is the
concentration of the saturated solution and Csol the concentration at any given time.
2.1. USE OF SURFACTANTS
Surfactant adsorption onto hydrophobic drug particles
below the critical micelle concentration can aid in wetting
of the particles and consequently increase the rate of
solution of particulate agglomerates

(31,60,79,89).

Surfac-

tants may be incorporated into solid dosage forms (26) so
that their solubilization action comes into play as disintegration process starts and water penetrates to form a concentrated surfactant solution around the drug particles or
5

granules.

(

Both facilitation of wetting through lowering of

surface tension and solubility increase will aid in dissolution of the drug. Other techniques of incorporating surf ace
- active agents have been reported. Chiou et al (13) have
discussed the enhancement of dissoltion of poorly water
soluble drugs by crystallization in aqueous surfactant solutions.

Ford and Rubinstein (28) have discussed the dissolu-

tion characteristics of a glutethimide - nonionic surfactant
melt system.
Surfactants cannot be considered to be "inert" pharmaceutical adjuvants which can be used indiscriminately in
formulations.

Even nonionic surfactants which are generally

more acceptable than ionic surfactants because of their
lower toxicity are not without intrinsic biological activity
of their own (27) which can be ascribed to their affinity
for and action on biological membranes.
Apart from their own biological or toxicological effects nonionic surfactants can sometimes act synergistically
with a drug substance to promote its absorption or activity,
or may decrease activity by entrapping the drug in micelles
which diffuse slowly and which cannot cross cell membranes
intact.
In any dosage form in which dissoution is the rate
limiting step prior to drug absorption,
increasing the dissolution rate,

surfactants can, by

increase the bioavaialabi-

li ty without any effects on the barrier properties of the
boundary membranes.

However,

6

if the surfactant does modify

the permeabilty of the membranes,
(

then any observed effect

on bioavailability is likely to be the result of both a
physical and a biological effect. Above the critical micelle
concentration,

there is the added complication of partitio-

ning of lipophilic drugs into micelles. The measured effect
of solubilzer will then be the result of these processes:
(1) increase in wetting and dissolution rate,
(2) increased permeability of biological membranes, and
(3) solubilization.
The efffect of the first two is to inrease and the last
to decrease absorption, although at very high solubilizer
concentrations solubilization occurs of those components
such as cholesterol and protein, essential for the integrety
of the membrane, causing a marked increase in drug absorption (26).
2.2. SOLID STATE MANIPULATION
Many compounds exist or are capable of being manipulated to exist in more than one form as solids. Some of
these forms are crystalline phases while others are metastable states where the compound is a noncrystalline or molecularly dispersed form. Pharmaceutical scientists have been
making use of the differences in the physical chemical
properties that exist between these solid states to optimize
drug delivery. Some of the ways in which the solubility
characteristics are modified by the solid state modification
are discussed.

7

2. 2 .1.

POLYMORPHISM

The ability of many compounds to crystallize in more
than one crystal form is known as polymorphism and has been
rewiewed by Haleblian (36).

The solubility of each form

depends on the ability of the molecules to escape from the
crystal of the solvent. The stable form possesses the lower
free energy at a particular temperature and pressure and
therefore has the lower solubility or escaping tendency.
When a metastable form is placed in contact with solvents, it can rapidly undergo reversion to the more stable
crystal form. The transformation process in such an environment will depend to a great measure on the degree of supersaturation achieved by the metastable material. There are
also instances in which adsorbed water on the surface of the
solid will catalyse the transformation process (87).
Using polymorphic modifications a 50 - 100 % increase
in

dissolution

rate

can

be

realistically

achieved

(16,44,87). However for some drugs a four fold increase has
been achieved (1,58). The amporphous form of novobiocin (69)
and sulfa drugs (66,92) have been isolated and found to be
much more soluble than the respective crystalline form.
case of novobiocin the amporphous form was 10 -

In

fold more

soluble than the crystalline drug (69).
2. 2. 2. SOLVATES

Many drug compounds upon recrystallization retain a
stoichiometric amount of the solvent. These crystalline
materials,

referred to as solvates or pseudomorphs,
8

may be

looked upon as molecular complexes. An important class of

(

solvates are the hydrates which contain water. In an aqueous
environment these compounds are the most stable forms and
therefore have lower solubilities in aqueous solvents than
the anhydrous (crystalline or noncrystalline) forms. When
the solvent is not water,

the solvent may dissociate in

aqueous environment, and, depending upon the solubility
product for the solvate in the media, the concentration of
the drug in the solution may well reach a level much greater
than that attainable from a nonsolvated form of the drug.
Shefter and Higuchi (88) studied the dissolution of the
pentanol solvate of succinyl sulfathiazole and found an
eightfold increase in solubility over the hydrate.

However

the nature of the bound solvent in the crystal and the
(

ability of the dissolution media to dissociate the solvent
dictates the extent to which there will be a favorable
effect.
2.2.3. RACEMATES AND ENANTIOMERS
The racemates and enantiomeric forms of a compound may
differ substantially in their solubilities (59,81). If, in
addition to possessing higher solubility (and hence dissolution rate),

an enantiomer is more active biologically than

the racemate then attempts should be made to isolate the
enantiomer and this should be used in the formulation.
2.2.4.

REDUCTION OF PARTICLE SIZE
The effect of particle size reduction of drugs on their

9

I

dissolution rates and biological availability was reviewed
comprehensivly by Fincher (25). A reduction in particle size
of drugs leads to an increase in the total surface area (S)
and the Noyes - Whitney equation predicts that this will
result in an increase in dissolution rate. For drugs with
poor water solubility a reduction in particle size generally
increases the rate of absorption and /or total bioavailabili ty. For example, the therapeutic dose of griseofulvin was
reduced to 50% by micronization (5) and a more constant and
reliable blood level was produced. The commercial dose of
spironolactone was also decreased to a fourth by just a
slight reduction of particle size (56). Such enhancement of
drug absorption could further be increased several folds if
a micronized product was used (8,56).
Partical size reduction is usually achieved by one of
the following methods (4) :
and grinding;

(a) conventional trituration

(b) ball milling;

(c) fluid energy microniza-

tion (d) controlled precipitation by change of solvent or
temperature,
drying;

application of ultrasound waves,

and spray

(e) administration of liquid solutions from which,

upon dilution with gastric fluids, the dissolved drug may
precipitate out in very fine particles; and (f) administration of water soluble salts of poorly soluble compounds
from which the parent, neutral forms may precipitate in
ultrafine form in the GI tract.
Although the reduction of particle size can be easily
accomplished by the first four (a-d), the resultant fine

10

(

particles may not produce the expected faster dissolution
and absorption. This primarily results from the possible
aggregation and agglomeration of the fine particles due to
their increased surface energy and the subsequent shorter
van der Waal's attraction between nonpolar molecules. Another inherent disadvantage of these pure fine powders of
poorly soluble drugs is their poor wettability. For these
reasons the methods mentioned above are seldom used for
dissolution rate enhancement.
2.2.5.

SOLID DISPERSIONS
The term "Solid Dispersions" was defined by Chiou and

Riegelman (14) and refers to "the dispersion of one or more
active ingredients in an inert carrier or matrix at solid
state, prepared by the melting, solvent or melting - solvent
method." Not included in this category are the dispersions
of drugs in solid diluents by the traditional mechanical
mixing (9).
The selection of the matrix has an ultimate influence
on the dissolution characteristics of the dispersed drug. A
poorly water soluble drug combined with a water soluble
carrier results in a fast release of the drug. On the other
hand the release of a water soluble drug can be retarded by
the use of a water - insoluble matrix.
Two basic procedures are used to prepare solid dispersions:

fusion and cosolvent techniques. Modification of

these methods and combinations of them have also been used
for the preparation of dispersed systems (14).
11

The fusion technique involves the heating the compo(

nents which make up the dispersion (drug plus carrier) to a
temperature at which melting occurs and a solution forms.
The melted mixture is usually cooled rapidly to entrap the
drug particles in the matrix in a very fine state.

The

cooling rate of the mixture can influence the physical state
of the solid obtained and the particle size of the crystals
formed (87). The principal disadvantage of this procedure is
the possibility of decomposition

and /

or evaporation of a

component at the elevated temperatures required. Low melting
polyethylene glycols are used commonly as carriers (9).
The cosolvent approach involves dissolving the ingredients comprising the dispersion in a common solvent. The
solvent is then evaporated off with the aid of a vacuum
(

pump. Sometimes heat is used to assist in the evaporation of
the solvent. Materials prepared by this procedure are sometimes known as

~Q£reci2..!tate§.

(14). The ingredients of the

dispersion should be very soluble in the solvent, or crystallization of one may take place before the other and a
uniform dispersion will be derived.
In many instances it is difficult to completely remove
the solvent from the dispersion. This in turn may have an
effect on the stability of the dispersion, both chemical and
physical.
Solid dispersions are generally of the following four
types:

eutectics, polymeric systems, glass dispersions, and

solid surface dispersions.

12

(a)

(

~utectics:

Eutectics are prepared by rapid solidifica-

tion of two melted components which show complete miscibility in the liquid state.

A number of systems exhibiting

eutectic behaviour have been examined. Urea and succinic
acid have been found to form simple eutectics with a wide
variety of drugs. This approach was first demonstrated by
Sekiguchi and Obi (85) in 1961 for formation of a eutectic
mixture of sulfathiazole with urea to increase dissolution
rate and absorption.
The increase in dissolution rate observed for eutectic
mixtures can result from a number of factors.

The main

causes postulated (87) for the observed dissolution of of
these systems are as follows:
(i) The particle size of the drug in the eutectics formed by
rapid solidification will be small. This can result in an
enhanced dissolution rate as a result of both surface area
increase and solubilization.
(ii) The carrier material as it dissolves may have a solubilizing effect on the drug.
(iii) In a eutectic where each crystallite of drug is surrounded by a water soluble crystal,

there will be good

wettability and dispersibility of the drug in the dissolution media.

The enhanced wettability of the drug should

retard any agglomeration and aggregation of the particles
which can slow the dissolution process.
(iv) The process of eutectic formation may cause the drug to
crystallize in a metastable state. As indicated earlier,

13

these phases in themselves would have a greater solubility
(

and therefore result in faster dissolution rates.
(b)

Roly~eric .e.yste~s:

Water soluble polymers have been

extensively used to form solid dispersions. Most of the
reported investigations have focussed on dispersions made
with polyethylene glycols or PVP. Studies with these polymeric substances

(14)

indicate that the ratio of drug to

polymer should be low to maximize the increase in dissolution of the drug. PVP is a noncrystalline polymer able in
many instances to disperse a significant amount of a drug in
a "high energy form" (61,83,91,95). The amount of drug which
can be loaded into PVP as a high energy noncrystalline form
is a function of the structure of the drug and the cosolvent
used to prepare the coprecipitate (87). In some instances,
the drug could be loaded into the polymer such that it would
exist almost exclusively in the higher energy state as long
as the ratio of drug to PVP was less than one (87).
Inhibition of the growth of the drug crystal structure
by PVP in solid dispersions (20) has been linked to improved
dissolution behaviour (19,90,92) and the formation of highly
supersaturated drug solutions (19,62). The implication is
that PVP prevents drug crystallization during preparation by
a drug polymer interaction,

possibly involving hydrogen

bonding, in the liquid state (86,91). Once the solvent is
removed,

the interaction helps stabilize the amorphous high

energy state ( 4 7).
The degree of solubilization observed for these systems
14

is usually high.

(

Reports of 6 to

10

fold increases in

solubility is not uncommon. An interesting facet of these
dispersions is that the high solubility achieved is maintained in solution for long periods of time (83,90,95).
High molecular weight PEG's which are highly crystalline in nature, are believed to be capable of entrapping low
molecular weight compounds in their interstitial spaces

(14). When PEG dispersions are prepared with their drug
fractions greater than their "solid solubility",

ultrafine

suspensions of the drug are produced. Although these dispersions exhibit much faster dissolution rates than the pure
drug,

they are relatively slower dissolving than those dis-

persions containing the drug in its molecularly dispersed
form.
(c) Glass Dispersions:

A number of water soluble compounds

are known to form glasses when their melts are rapidly
solidified. Among these are citric acid and a host of sugars.

The glassy or vitreous state is characterized by

transparency and brittleness below the glass forming temperature. On heating, it softens progressively and continuously without a sharp melting point. This is primarily due to
the fact that the chemical bonds in the glass differ considerably in length and, therefore, in strength and that there
is no one temperature at which all the bonds become loosened
simultaneously (14). The lower density of glasses resulting
from molecular framework in the glasses could provide the
environment for the dispersal of drug molecules.
15

Such dis-

(

persions would be expected to rapidly dissolve in aqueous
media. Drugs dispersed in glass matrices of dextrose, galactose, and sucrose have been reported to exhibit very rapid
dissolution rates (2). Examples of glass solutions are primidone - citric acid (97), griseofulvin - citric acid and
phenobarbital - citric acid (9).
(d) Solid Surface Dispersions:

The dissolution characteris-

tics of drugs can be altered by dispersing it on the surface
of certain materials. Deposition of the drug by solvents on
solid supports and by grinding it with certain materials has
produced dramatic results.
Monkhouse and Lach (65) used water - insoluble adsorbents, such as fumed silicon dioxide and silicic acid, as
supports for the solvent deposition of a number of drugs.
The support material is suspended in a solution of the drug
followed by evaporation of the solvent. The resulting material contained the drug in a "molecularly micronized" state
on the surface of the carrier.
Yamamoto et al (106) observed that when griseofulvin
was ground with microcrystalline cellulose in a vibrational
ball mill its dissolution rate and bioavailability were
substantially enhanced. The grinding procedure was shown to
result in a total loss of griseofulvin crystallinity. Other
drugs which have been dispersed similarly on microcrystalline cellulose are aspirin,

salicylic acid,

chloramphenicol

palmitate, diazepam, mefenamic acid and sulfisomezole (70).
Another approach for dispersing drug on solid surfaces
16

is the roll - mixing method of Nozawa et al (72,73). This

(

method was shown to enhance the dissolution rate of phenytoin (72) and nifedipine (73).

2.3. COMPLEX FORMATION
The alteration of apparent solubility which can be
achieved through complexation may be utilized to decrease or
to increase solubility. The usefulness of the solid complex
obtained will be dependent upon its apparent solubility
relative to that of the inherent solubility of the substrate. For instance, Higuchi and Pitman (43) have suggested
the use of a relatively insoluble caffeine - gentisic acid
complex for reducing the bitterness of caffeine in a chewable tablet. However the more common use of solid complexes is
associated with the enhanced solubility of the complex.
An example of a system in which the use of solid complex has been found to substantially enhance dissolution
rate is the digoxin - hydroquinone system (42). The dissolution rate of digoxin from the complex (two mols digoxin :
three mols hydroquinone) was much more rapid and complete
than that of digoxin when powders of equal mesh size and
equal digoxin concentrations were compared.
Another example of enhanced dissolution rate through
the use of complex is the 1:1 acetaminophen - caffeine
complex (15).

It was found that the solid complex at 25

degrees Celcius was a hexahydrate form. However, when the
complex was dried to yield either the monohydrate or anhyd-

17

rous complex,

(

the apparent solubilities and the associated

dissolution rates of both these species were much greater
than with the hexahydrate complex of pure acetaminophen.
These results point out the need to carefully characterize
the nature of the solid complex for the extent of solvation,
as well as the substrate - ligand stoichiometry,

before

reaching any conclusion about the usefulness of the complex
( 80) •

The use of complexation has several advantages. Among
these are the reversibility of the interactions.

Dissocia-

tion of the complex to the individual reactants occurs
rapidly and spontaneously upon dilution.

Consequently,

the

biological effects of complexes can be predicted on the
basis of the knowledge of the pharmacologic properties of
each of the interactants. The above characteristics of the
complexes are in contrast to chemically derived prodrugs
which normally require some sort of "triggering" features to
aid in release of the parent drug. Another advantage of the
use of complexation is the physical stability of these
systems in comparison with polymorphs and other crystal
modification which are often thermodynamically unstable and
therefore may undergo time - dependent changes in solubility
behavior.
This approach, however, is not without limitations.
Ironically,

in some instances,

it may be that rapid and

total reversibility previously presented as an advantage may

(

prove to be a problem especially in those cases in which
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dilution of a system may result in precipitation.

(

A second problem is the necessary presence of the
ligand whose sensory and/or pharmacologic effects may be
unacceptable.
Finally, in most reported cases, the apparent solubility increases realized by complexation were an order of
magnitude or less (80). Consequently, when solubility increases of 10 2 or 10 3 are required, approaches other than
complexation should be used.
2.4. FORMATION OF INCLUSION COMPOUNDS
Inclusion compounds are addition compounds in which one
entity fits into and is surrounded by the crystal lattice of
the other (17). These are complexes characterized by the
lack of adhesive forces between the components of the complex.

It is not a chemical interaction which causes an

inclusion compound to form, although this may be a factor in
the net complexation observed. The steric configurations of
the molecules are such that the enclosing, or "host" molecule, can spatially enclose the included or "guest" molecule,

leaving unaffected the bonding systems of the compo-

nent. Thus geometrical rather than chemical characteristics
of the molecules are the limiting factors in the interaction
( 17) .
The formation of inclusion complexes of a drug with
nontoxic agents is a type of manipulation used to improve

(

the dissolution properties of drugs (30,104). Cyclodextrins,
which are products of enzymatic degradation of starch, have
19

been used extensively as such complexing agents. In these

(

complexes molecules of the drug are enclosed in the hydrophobic cavity of a cyclodextrin molecule or in a channel
formed by several molecules of cyclodextrins.

Depending on

the size of the open space within each molecule the cylodextrins have been classified as alpha, beta and gamma.
Because of their different internal ring sizes the
cyclodextrins show different degrees of inclusion formation
with different sized molecules. Beta cyclodextrin, which is
the most practical to use,
solubility,

unfortunately has low water

and its complexes are also often only slightly

soluble. Recently attempts have been made to improve the
solubility of beta cyclodextrin by chemical derivatization
(68, 71, 75, 77).

However,

there have been only a limited number of

studies to indicate the lack of toxicity of these new compounds in humans and much more work is needed before these
compounds can be used in commercial products.
2.5.

DRUG DERIVATIZATION
The use of derivatives to enhance the aqueous solubili-

ty of insoluble drugs and has long been recognized as an
effective design strategy. The prodrug strategy is based on
chemical or biochemical reconversion to the active drug
prior to reaching the site of action.
Generally two strategies can be used to increase the
(

aqueous solubility :

(a) introduction of an ionic or ioniza-

ble group and (b) introduction of a group which decreases
20

the melting point.
{

The synthesis of an ionic or ionizable derivative of a
drug is perhaps the most common of the prodrug strategies.
Some of the progroups used are hemisuccinates,

phosphates,

dimethylaminoacetates, amino acid esters, choline esters,
and betadimethylaminoethyl esters (3).
Examples of increases in solubility by lowering the
melting point are seen in allopurinol (46) and ara-A (82).
The basis for this strategy is that in order to dissolve,
molecules must be removed from the crystal lattice. Any
modification which reduces the crystal lattice energy, hence
melting point, would tend to increase solubility (in all
solvents).

The relationship between the aqueous solubility

Sw and melting point is expressed by the equation (3):
logSw

=

-logPC -

O.OlMP + 0.5

(2)

where PC is the octanol/water partition coefficient and MP
the melting point in degrees Celcius.

3. CONTROLLED RELEASE DOSAGE FORMS

A controlled release dosage form is generally defined
as one that attempts to (57):
(1) sustain drug action at a predetermined rate by maintaining a relatively constant, effective drug level in the body
with concomitant minimization of undesirable side effects
associated with a sawtooth kinetic pattern.
(2) localize drug action by spatial placement of a controlled release system adjacent to or in the diseased tissue or

21

organ.
(

(3) target drug action by using carriers ar chemical derivati zation to deliver drugs to a particular "target" cell
type.
In practice, very few of the applied systems embrace
all of these actions.

In most cases,

the release system

creates constant concentration of drug within the body over
an extended period of time. It is desirable that the duration of drug action become more a design property of a rate
controlled dosage form,

and less, or not at all, a property

of the drug molecule's inherent kinetic property.
3.1. ORAL CONTROLLED RELEASE SYSTEMS
Oral ingestion has long been the most convenient and
commonly used route of drug delivery.
- release systems,

Indeed,

for sustained

the oral route of administration has by

far received the most attention with respect to research on
physiological and drug constraints as well as design and
testing of products. This is because there is more flexibility in dosage form design for the oral route than there is
for other routes.
As in the case for systems for nonoral routes,

the

design of oral sustained release delivery systems is subject
to several intercalated variables of considerable importance. Among these are the type of delivery system, the physicochemical property of the drug,

the disease being treated,

the patient factors and the length of therapy.
The majority of oral controlled release systems are
22

either tablets or capsules although a few liquid products
are also available.

Sustained release tablets and capsules

usually consist of two parts : an immediately available dose
to establish the blood level quickly and a sustaining part
that contains several times the therapeutic dose for protracted drug levels. Several approaches are available to add
the immediately available dose to the sustaining part. Simple addition of a nonsustained dose of a drug to a capsule
or tablet is the most direct method; placement of the initial dose in the tablet coat with the sustaining portion in
the core represents the alternate approach. Potential physical methods that can be used to retard drug release are
summarized below (42):
1. Capsules of polymeric material filled with a solid or
liquid drug or with a suspension of drug in a fluid,

in

which drug release is controlled by diffusion through the
capsule wall
2. A heterogeneos dispersion of drug particles in a solid
matrix which can be either biodegradable or nonbiodegradable
and which controls drug release by diffusion through the
matrix, by erosion of the matrix, or by a combination of
both diffusion and erosion
3. A laminate of agent and polymeric material made by coating a film of biodegradable or nonbiodegradable material
with solid drug and then by forming the film into a sealed
"sandwich" or "jellyroll",
diffusion, erosion, or both
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in which drug release is by

4. A heterogeneous dispersion or solution of drug in a water

(

- swellable hydrogel matrix, which controls drug release by
slow surface-to-center swelling of the matrix by water and
subsequent diffusion of the drug from water-swollen part of
the matrix
5. Liquid-liquid encapsulation of the drug in a viscous
solution of polymer, which controls drug release by slow
diffusion through dilution of the media
6. Pumps that either mechanically or chemically (osmotic
pressure) provide drug in a controlled manner
7.

Drug coated micropellets which have an apparent density

lower than that of gastric juice for an extended period,
while slowly releasing drug
8.

(

Drug-containing bioadhesive polymer that adheres to the

mucin coating of the GI tract and which is retained on the
surface epithelium to extend GI transit time of the drug.
Drug is released at a constant rate from the bioadhesive
polymer for subsequent absorption
9.

Chemical bonding of a drug to a polymer backbone by

pendent amide or ester linkages, which controls drug release
by hydrolysis
10.

Formation of macromolecular structures of the drug via

ionic or covalent linkages,
hydrolysis,

which controls drug release by

thermodynamic dissociation, or microbial degra-

dation

{
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3.2. POLYMERS IN ORAL CONTROLLED RELEASE SYSETEMS
Other than mechanical pumps, all controlled release
devices use polymers in the rate control mechanism. Polymeric devices can be classified into 3 categories:
sion-controlled devices,

(a) diffu-

(b) solvent-controlled devices, and

(c) chemically-controlled devices. Of these, the first two
types are used for oral drug delivery while the chemically
controlled devices are usually employed for implantable
systems or other non-oral systems and will not be discussed
here.
3.2.1.

DIFFUSION CONTROLLED DEVICES
These may be further classified into monolithic devices

and reservoir devices.
In a monolithic device the therapeutic agent is intimately mixed (either dissolved or dispersed) in a rate controlling polymer, and release occurs by diffusion of the agent
from the device. For an active agent dissolved in the matrix, release kinetics can be calculated by two equtaions
(39). Equation (3), known as the early time approximation,
holds true for the first 60% of the release rate,

after

which it is calculated from eq.(4), which is known as the
late time approximation.
dMt/dt

=

2Mx(D/pi.l 2t) 1/2

(3)

dMt/dt

=

(8DMx/1 2 ) exp (-pi 2 Dt/1 2 )

(4)

These equations predict active agent release from a
slab of thickness 1 where D is the diffusion coefficient, Mx

l

is the total amount of active agent dissolved in the polymer
25

and Mt is the amount released at a time t. As equation (3)

(

shows, release rate decreases as t- 1 / 2 over the first 60% of
the release;

over the remainder of the release the rate

decays exponentially according to eq.

(4).

When the active agent is dispersed in a the polymer,
release kinetics have been derived by Higuchi (41):
(5)

where A is the area,

Cs is the solubility of the active

agent in the matrix and

c 0 is total concentration in the

matrix (dissolved plus dispersed) .
Although active agent release from monolithic systems
does not proceed by zero-order kinetics,

it is the simplest

and most convenient way to achieve prolonged release of an
active agent.
In a reservoir device the active agent is contained in
a core that is surrounded by a rate controlling membrane.
Transport of the material in the core through surrounding
nonporous, homogeneous polymer film occurs by dissolution at
one interface of the membrane and then diffusion down a
gradient in thermodynamic activity (39). It can be described
by Fick's first law modified:
J

=

-DKC'

I

(6)

1

where J is the flux, D is the diffusion coefficient of the
permeant in the membrane, C' is the concentration difference
between solutions on either side of the membrane, K is the
distribution coefficient analogous to a liquid - liquid
partition coefficient and 1 is the thickness of the membrane.
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If the thermodynamic activity of the active agent in

(

the reservoir remains constant, if there is no change in the
rate - limiting membrane characteristics, and if infinite
sink conditions are maintained at the downstream side of the
membrane,

rate of active agent release will be constant and

can be predicted from a knowledge of membrane permeability
and device configuration.
Even though such reservoir type devices should theoretically be capable of delivering active agents at a constant
rate, also referred to as zero-order kinetics, in practice
several factors contribute to deviations from zero-order
kinetics. The two most important factors are boundary layer
effects and the burst effect.
Boundary layer problems arise in applications in which

(

the rate of removal of the active agent from the membrane is
slow so that the concentration of the drug at the membrane
surface increases with time. Then as predicted by eq.(6),
the term dC decreases and consequently the flux J

also

decreases.
Burst effects occur when during storage the active
agent contained in the core saturates the membrane surrounding the core; then, when the device is placed in the desorbing medium,

the active agent will rapidly desorb from the

membrane.
Reservoir devices are capable of very long term zeroorder drug delivery.

However they may require more complex

fabrication procedures than monolithic devices.
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3.2.2.

SOLVENT-CONTROLLED DEVICES
Solvent-controlled devices release active agents as a

consequence of controlled penetration of a solvent into the
device.

Although non-aqueous solvents can be used,

only

water is of importance in controlled release applications
for human or veterinary applications. The two general mechanisms used for solvent-controlled devices are osmosis and
swelling.
a.

Q~~otical.J:y-Controlleg

_Qevices:

In these devices the

active agent is placed in an innermost impermeable flexible
reservoir surrounded with an osmotic agent, which in turn is
surrounded with and sealed within a rigid cellulose acetate
semipermeable membrane (39). When the device is placed in an
aqueos environment, water is osmotically imbibed across the

(

semipermeable membrane, and the active agent contained within the flexible reservoir is pumped out of the device.
Because the driving force is the osmotic transport of water
across the membrane, performance of the device is essentially independent of the environment within which the pump
operates.
b. Swelling-Controlled Devices:

In these systems an active

agent is homogeneosly dispersed in a glassy polymer. Because
glassy polymers are essentially impermeable, the active
agent is immobilized in the matrix, and no diffusion through
the solid polymer phase takes place.
When such a monolithic device is placed in an aqueous
environment,

water begins to penetrate the matrix and swel-

28

ling takes place. As a consequence, chain relaxation takes

(

place and the incorporated active agent begins to diffuse
from the swollen layer.

(

(
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II. PURPOSE OF THIS STUDY
As can be seen from the preceding discusion, it would
be desirable to formulate an oral solid dosage form, preferably a tablet, offering some degree of control over the
release of nifedipine. The final properties will be influenced by the techniques used for enhancing the dissolution
rate,

by the material and proportion of the rate - control-

ling matrix,
tegration,

and by the tablet properties (hardness, disin-

etc) .

For the enhancement of dissolution of nifedipine in the
present study,

the solid dispersion technique has been em-

ployed using PEG 8000 and PVP 40T as the polymer for forming
coprecipitates. In a preliminary study Sugimoto et al (96)
found that nifedipine - PVP coprecipitates gave the fastest
release rates. Further, the molecular weight of PVP that
gave the best results was 40,000.

Compared to the bioa-

vailability from a physical mixture (of nifedipine and PVP)
the Cmax and AUC of the coprecipi tates were 5 -

fold and 3 -

fold higher.
The rationale for using PEG for preparing coprecipitates is the fact that the physicochemical stability of PEG
coprecipitates are very high (99). The use of PEG 8000 for
the preparation of nifedipine coprecipitates is not reported
in the literature. However,

Sumnu (98) found no significant

differences between PEG 4000,

6000,

and 10000 when release

of nifedipine coprecipitates with these substances were

(

compared.
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For sustaining the release, powdered microporous polyp-

(

ropylene polymer (Accurel) has been used. This new material
has small cells and canals formed throughout its structures
which are connected by small pores occupying 30 - 90% of the
volume (49,94). For this study,
taining

powdered polypropylene con-

75% v/v void space has been used. A major advantage

of this substance is its property to give good coherence
after tabletting (49). Matrix tablet with relatively high
drug load show diffusion controlled characteristics and
release was approximately zero - order (49).
The objectives of this study were :
1.

To prepare an optimized formulation of nif edipine using

the coprecipitate approach to improve the dissolution rate.
2. To study the tabletting properties of the variuos formu-

(

lations.
3. To perform in

~itro

dissolution tests to evaluate the

release rate of nifedipine from the tablet dosage forms.

It

is desired that about 50%

be

of the dose (i.e.

10 mg)

released within 20 minutes and the remaining 50% be released
over an extended period of time (compared to the release of
commercial soft gelatin capsules under similar conditions).

(
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III. EXPERIMENTAL

(

1.

MATERIALS

A. Chemicals
Acetic acid,
Accurel,

Glacial Reagent A.C.S.

Polypropylene powder,

(lot # 705283) 1

75% void space (lot #

40306/1-3/P) 2
Ac-di-sol TM, Type SD - 711, modified cellulose gum
(lot # 7135 - 25) 3
Acetonitrile HPLC grade (lot # 853747) 1
Ammonium acetate (lot # 731745) 1
Cab-0-Sil brand colloidal silica 4
Ethanol 200 proof, Dehydrated alcohol u.s.P 5 .
Hydrochloric acid 6
Methanol HPLC grade (lot # 864444 & 863081) 1

(

Polyethylene glycol 8000 (lot# 106 F - 0020) 7
Polyvinyl pyrrolidone, PVP - 40T (lot# 74F-0208) 7
Phosphoric acid HPLC grade (lot # 715056) 1
Potassium phosphate monobasic (lot # 722964) 1
Potassium phosphate dibasic (lot # 722337) 1
Sodium hydroxide, Certified A.C.S.

(lot # 720859) 1

Sodium phosphate dibasic (lot # 772374) 1
Sodium lauryl sulfate, u.s.P.

B.

Dr~~

Nifedipine crystalline powder (batch # 167707A) 8
Nifedipine soft - gelatin capsules (Adalat) 8
1.

Fisher Scientific Company, Fairlawn, New Jersey.
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(

2.

Enka Industrial Products Inc., Illinois.

3.

FMC Corporation, Philadelphia, Pennsylvania.

4.

Cabot Corporation, Boston, Massachusetts.

5.

U.S. Industrial Chemical Company, Tuscola, Ill.

6.

E.I. du Pont de Nemours

7.

Sigma Chemical Company, St. Louis, Missouri.

8.

Bayer AG., Germany; supplied by Miles Pharma-

&

Co., Wilmington, Del.

ceuticals, West Haven, Connecticut.

2.

EQUIPMENT
Electronic Analytical Balance, Sartorus GMBH, Germany.
Electrical Balance, Model HS Mettler, Will Scientific
Inc.,

Rochester, New York.

Dissolution Tester Six Spindle, Vanderkamp 600, Van-kel
Industries Inc., Chatham, New Jersey.
Tablet Disintegration Test Apparatus, Van-kel Industries
Inc., New Jersey.
HPLC Solvent Delivery System Model 6000A,

Waters Asso-

ciates, Milford, Massachusetts.
WISP 710B, Waters Associates, Milford, Massachusetts.
mu- Bondapak Cl8 Column, Waters Associates, Milford,
Massachusetts.
LC Spectrophotometer Lambda Max Model 480, Waters Associates, Milford, Massachusetts.
Linear Chart Recorder,

Cole Parmer Instrument Co.,

Chi-

cago, Illinois.
I

Integrator Model HP 3392A, Hewlett Packard Co., Avon-
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dale, Pennsylvania.

(

Diode Array Spectrophotometer Model 8451A Hewlett Packard Co.
pH - Meter, Model 811, Orion Research Inc., Cambridge,
Massachusetts.
Gold Fluorescent Lamp Mopdel F40GO, General Electric.
Tablet Press Single Punch, Stokes.
Friability Tester, Erweka GmbH, Germany.
Water Bath, Precision Company.
Ultraviolet - Visible Spectrophotometer Model Hitachi
200, Perkin Elmer .
Laboratory Mill, Arthur H. Thomas Co.,

Philadelphia,

Pennsylvania.
Rotavapor Rotary Evaporator,

Buchi.

Granule Mixer, Turbula, Switzerland.

3. PROCEDURES
Nifedipine is quite light - sensitive and degrades
rapidly on exposure to daylight, tungsten - bulb light, or
standard fluorescent light.

It is however,

"gold" fluorescent light is used (37).

stable when

Therefore all proce-

dures described here were carried out in a laboratory area
which was either dark or had only gold fluorescent lighting.

3.1. ASSAY DEVELOPMENT
For quantitative analysis of nifedipine an ultraviolet

(

(UV)

spectrophotometer was used in conjunction with a rever-
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sed phase high performance liquid chromatography system

(

(HPLC). First a 10 mg/L solution of nifedipine in methanol
was prepared and allowed to degrade under normal laboratory
light for 7 days. After this period a UV spectrum was obtained of the

degraded sample (190 - 400 nm). Next a UV

spectrum of a fresh solution of nifedipine of the same
concentration

was

superimposed

on

the

first

spectrum

(fig.2). From the resulting scans it was evident that the
difference in the absorbance values of nifedipine and its
photodegradation product was greatest at 238 nm with the
absorbance of nifedipine being much greater. A standard
curve of nifedipine was obtained at this wavelength for
concentrations between O and 20 mg/L.
Although several authors have used a UV assay at 238 nm
for nifedipine (53,54),

it is not stability indicating. For

this reason an HPLC assay was developed using a 3 - 9 mm
(id) x 30 cm mu-Bondapak C18 (reversed phase) column and a
variable wavelength detector (Lambda max 480) set at 238 nm.
A number of mobile phase systems were tested and the one
which provided the best resolution between the peaks of
nifedipine and its photodegradation compound was chosen for
the assay. This consisted of 49 percent methanol in fresh
distilled,

deionized water.

The chromatographic conditions

were as follows:
The flow rate was 1.2 ml/min., the detector sensitivity
was 0.05 AUFS and the injection volume (using WISP) was 100
microliters.
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Fig. 2. UV absorption spectrum of nifedipine
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A plot was obtained between peak height / area versus

(

concentration using standard solutions of nifedipine and was
used to determine the concentrations of the dissolution
samples.
Alternatively, concentrations of dissolution samples
were obtained by the spectrophotometric method and stability
was checked by the HPLC method.
3.2. PHOTODEGRADATION STUDIES
To study the rate of degradation of nifedipine solution
in normal laboratory conditions a preliminary study was
conducted in a lighted room at night to exclude the variable
intensity of sunlight.
20 mg/L of nifedipine solution was prepared in three
different media to test the effect of pH on the rate of
photodegradation of nifedipine. The first medium was 49%
methanol in water (corresponding to the mobile phase of the
HPLC system); the second and the third media were 49% methanol in 0.01 M phosphate buffer with final pH adjusted to 4.2
and 7 .8 respectively.
Four ml of each of the three solutions was taken separately in a WISP vial and kept exposed to the light in the
room. At o, 30, 60 and 180 minutes two samples of 25 microliters each were withdrawn from each solution and injected
into the HPLC system manually. A set of standard solutions
were also injected during the assay to obtain a standard
curve at the same conditions. From a peak height analysis of
the chromatograms the percent of nifedipine remaining in the
37

solution was calculated.

(

3.3. SOLUBILITY STUDIES
The solubility of nifedipine in various media was determined in an attempt to obtain a suitable medium for
dissolution studies.

The apparatus used was similar to the

dissolution apparatus used in the rotating bottle method
(38). The media selected were distilled water, hydrochloric
acid 0.1 N and 1.0 N, sodium hydroxide 0.1 N, and phosphate
buffer O.OlM (pH 7.4). The
was maintained at 25

temperature of the water bath

±. 1 degrees Celcius. Glass tubes with

screw caps were used for holding the soutions. Each tube was
filled with 20 ml of of the medium and about 10 mg of
nifedipine thereby ensuring the excess of the drug in the
tube. Three tubes were used for each media.
The caps were screwed on the tubes and were wrapped
securely with a strip of paraf ilm to prevent any leakage.
The tubes were fixed to the shaft and allowed to rotate in
the water bath. At 3.5 and 4.5 hours, the tubes were removed
and 3 ml samples were withdrawn from each tube using a pipet
fitted with plastic tube containing glass wool to prevent
solid particles from entering the pipet. The samples were
assayed immediately by UV spectrophotometer at 238 nm. Similarly the solubility of the coprecipitates were determined
at 25 degrees.
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3.4. PREPARATION OF NIFEDIPINE - POLYMER COPRECIPITATE
Fifty grams of nifedipine powder (crystalline) was
taken in a 2L round - bottom flask. To this about 400 ml of
ethanol was added with continuous stirring. Two hundred
grams of the polymer (PEG 8000 or PVP 40T) was then added
with stirring and the solution warmed in a water bath at
about 45 degees Celcius.

Stirring was continued until a

clear solution was obtained.
The solution was allowed to cool to room temperature
and the solvent was evaporated under vacuum using a rotary
evaporator at 40 degrees Celcius. The semi- dried mass was
crushed and collected in a lL beaker, covered with aluminum
foil (with holes punched at the top to allow drying) and
kept in a vacuum oven at room temperature for 48 hours. At
the end of this period the beaker containing the coprecipitate was removed from the oven and kept in a dessicator for
further use.

3.5.

TABLETTING
For preparing tablets the nifedipine - polymer copreci-

pitates were milled separately in a laboratory mill using a
#20 screen. The two coprecipitates were then mixed in the
desired ratio, according to the formulation (see table I),
and 20 grams of the resulting mixture taken in the mixing
jar. To this, 700 mg (i.e. 3.5%) of Ac-di-sol (disintegrant)
and 200 mg (i.e. 1.0%) of Cab-0-Sil (antiadherent) was added
and mixed together in a turbula mixer for fifteen minutes.
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(

Composition of controlled release tablets of

TABLE I.

nifedipine.

Tablet

Amount of ingredient per tablet (mg)

code

PEGa PVPb

Tl

100

T2

Ac-di-sol

Accurel

SLSc

Cabosil

0

3.5

0

1.5

1

50

50

3.5

0

1.5

1

T3

25

75

3.5

0

1.5

1

T4

5

95

3.5

0

1.5

1

T5

25

75

3.5

5

1. 5

1

T6

25

75

3.5

7.5

1.5

1

aPolyethylene glycol 8000 and nifedipine (4:1) coppt.
bPolyvinylpyrrolidone (40T) and nifedipine (4:1) coppt.
csodium lauryl sulfate.
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At the end of this time, the jar was taken out and 300

(

mg (i.e. 1.5%) of sodium lauryl sulfate (soluble lubricant)
was added. The whole contents were then mixed for another
five minutes.
For tablets T5 and T6 (see table I), Accurel (1.0 gm
and 1.5 gm respectively) was added along with Ac-di-sol and
Cab-O-Sil to the coprecipitate mixture.

The rest of the

procedure was the same as described.
Tabletting was done using a single - punch tablet press
operated maunually. The humidity of the room was kept below
40 percent with a dehumidifier.

The lower punch of the

machine was adjusted according to the theoretical weight of
the tablet (106 mg for Tl - T4, 111 mg for T5, and 113.5 mg
for T6). For each formulation about 120 tablets were obtained. The physical properties of the tablets were studied
and the tablets stored in opaque plastic bottles in a dessicator for dissolution studies.

3.6. EVALUATION OF TABLET PROPERTIES
3.6.1

PHYSICAL PROPERTIES:
Weight variation and disintegration time was studied

for each type of tablet in accordance with the official
method (USP XXI). Hardness was tested on five tablets of
each type using Erweka hardness tester. Friability was determined using 10 tablets with Erweka Friability tester at 25
rpm for 4 minutes for each test.
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6.2 DISSOLUTION STUDIES:

(

Dissolution rate was studied for each kind of tablet
under two different conditions as described below.

In each

case the dissolution flasks were filled with 1 L of freshly
prepared distilled water and warmed to 37

±

1 degrees Cel-

cius. The USP paddle method was used with the stirring speed
maintained at 150 rpm. All samples were run three times.
In the first case one whole tablet (containing 20 mg
equivalent of nifedipine) was taken in each of three flasks
and the procedure was carried out for all six types of
tablets Tl through T6. At appropriate intervals,

a 3 ml

sample was withdrawn by means of a pipette fitted with a
small piece of glass wool to filter off any drug particle.
The sample volume taken was replaced by an equivalent volume
(3ml) of fresh distilled water at the same temperature. The
sample was suitably diluted with warm distilled water and
assayed using UV spectrophotometer at 238 nm as well as HPLC
assay as described before. For comparison of the dissolution
profile of the tablets prepared from the coprecipitates a
similar procedure was carried out using pure nifedipine
powder (20 mg) and also commercially available soft - gelatin capsules of nifedipine (2 capsules per flask - equivalent of 20 mg nifedipine).
In the second case the tablets were cut into small
pieces. A small piece (containing approximately 4 mg equivalent of nifedipine) was weighed accurately and taken in 1 L
of dissolution media (to approximate sink conditions) and
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the above procedure was repeated. From the weight of the
tablet fraction the amount of nif edipine was calculated to
give the dissolution rate expressed as a percent of the
amount dissolved in a given time interval.
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IV. RESULTS AND DISCUSSION

(

This section contains an evaluation of the experimental
protocol and assay techniques used in this study and results
thus obtained. It also contains a critical discussion of the
significance and an interpretation of the results.
For ease of reference the results and discussion are
organised into the following sections:
A. Evaluation of the assay methods.
B. Kinetics of Photodegradation of nif edipine.
C.

Solubility studies.

D. Evaluation of the physical characteristics of
tablets.
E.

Disssolution studies.

A. EVALUATION OF THE ASSAY METHODS
1. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
Table II summarizes the results obtained from the various mobile phases and flow rates used in developing a
stability indicating assay HPLC assay for nifedipine.
The retention times for nifedipine and its photodecomposi tion product are denoted by Tr2 and Trl respectively.
The resolution R was calculated using the formula
R

=

2 (Tr2 - Trl)/ (Wl + W2)

(7)

where Wl and W2 are the base peak width of the degradation
product and nifedipine respectively.
From the table it is evident that using 49% methanol in
water as mobile phase gives the best resolution. Hence this
44
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Table II.

Resolution obtained from the various mobile phase
systems.

RC

Trla
(min)

Tr2b
(min)

1.1

5.4

6.0

<0.5

55:45

1.4

5.6

6.6

0.5

-do-

50:50

1. 0

10.1

12.8

0.96

-do-

49:51

1.4

11.1

14.9

1.15

-do-

48:52

1.5

10.4

14.0

1. 09

-do-

45:55

1.5

12.0

15.8

0.95

48:52

1.4

7.8

9.8

0.71

45:55

1.4

10.4

13.8

1. 07

methanol/acetate
-buf. (0.05M,pH6.0)

50:50

1. 4

8.0

10.0

0.92

methanol/phosphate
-buf.(O.OlM,pH4.7)

62:48

1. 0

5.3

6.0

<0.5

acetonit/acetate
-buf. (0.05M,pH4.0)

5:7

1.2

7.6

7.6

1:2

1. 5

12.4

12.4

Mobile Phase

Ratio

methanol/water

60:40

-do-

methanol/acetate
-buf.(0.05M,pH4.0)
-do-

-do-

Flow
(ml/min)

0

aTrl is the retention time of the photodegradation product.
bTr2 is the retention time of nifedipine.
CR is the resolution given by the equation
R = 2 (Tr2 - Trl) I

(Wl + W2)
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(see text) .

0

was selected for the assay of nifedipine. A typical chromatogram is shown in figure 3.
A linear relationship was found to exist between peak
height (as well as peak area) and nifedpine concentration.
Figures 4 and 5 show that this linearity was held in the
concentration range O - 10 mg/L. However,

the relationship

between peak area (or peak height) and concentration varied
everytime a fresh mobile phase was used. To overcome this
problem a standard curve was generated during each run and
the sample concentrations were determined from the corresponding relationship between peak area or height and concentration of the standard solutions.
Another problem with the HPLC assay was that it was
very slow. For this reason it was used in conjunction with
the UV assay described below.

2. ULTRAVIOLET SPECTROPHOTOMETRIC METHOD
The use of UV spectrophotometer at a wavelength of 238
nm provided a simple, relible and sensitive assay which was
also rapid and reproducible. Detection was linear in the
range of concentrations tested (O - 20 mg/L). The absorbance
(A) was related to the concentration (C) by the equation
(see fig. 6):
A =

0.0607C

+ 0.007

The coefficient of correlation r

=

(8)

0.9998

To check for degradation of nif edipine during disso1 u ti on or solubility studies, one of the three samples for

46

(
C)

•

C)

......

C)

m•

Vl

+>

~

O'l
Q)
~
~

n3

"""
_J

Q)

0.
O'l

C)

Vl

(0•

c

=3
Q)

(

"

{_'.)
~

'-./

z

>
s...
=3
u
c

C)
t-i

t-

,_<

0

0::

+>
n3
s...

a

...Cl

.-

•

"':t'

n3

u
u

z

lll
LJ

z

C)

_J

L.l

a...

:c
¢

O'l
•rl.J...

C)

•

(\J

Cl

0

•

00

..--1

a

•

<O

.....

a

0

•

0

C)

•

-.:f"

N

..--1

..--1

CHJ)

0

•

•

CD

a

•

(0

..--1

lH~I3H
48

>iV3d

a

0

•

"'¢

N

•

•

cf::J
•
0

--.....

Fig. 5. HPLC calibration curves using peak areas.
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0
0

0
0

each time point in each batch was also assayed by the HPLC

(

method. The results obtained from the two methods for one
study were compared (see under dissolution studies in this
section) and it was found that the difference in the concentrations obtained from the two methods is very small.

B. KINETICS OF PHOTODEGRADATION OF NIFEDIPINE
The results of a preliminary study of the kinetics of
photodegradation of nifedipine are presented in table III.
On plotting the results on a log - linear scale (fig. 7), it
is seen that the photodegradation follows first order kinetics. The t 90 of degradation was found to be about 19 minutes in a normally lighted room during the night.
Thoma and Klimek (102) studied the degradation kinetics
of nifedipine in daylight. They reported a t 90 of about 7
minutes in winter and about 1 minute in the summer. The
purpose of our investigations was to see if, by excluding
daylight from the room, the degradation of nifedipine could
be prevented for a sufficient length of time to perform
dissolution or solubility experiments.

From the results it

is clear that even in the absence of daylight nifedipine
solutions are extremely photosensitive to normal laboratory
light.
Another objective of this preliminary study was to see
if there is a measurable difference in the rate of degradation of nifedipine when the pH of its solution was acidic or
alkaline.
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Table III.
Time (min)

Photodegradation of nifedipine.

% nifedipine remaining in solutiona
A

B

c

0

100

100

100

30

84.0

84.1

83.9

60

74.2

75.1

74. 7

120

50.2

asolution of 20 mg/L prepared in the following solvent:

A. 49% methanol in water.

(
B. 49% methanol in phosphate buff er (final pH 4.2).

c.

49% methanol in phosphate buff er (final pH 7.8).

(
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Fig. 7. Rate of photodecomposition of nifedipine showing First order decay.
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From the results obtained (Table III) it is clear that

(

in the pH range of 4.2 - 7.8 there was no appreciable difference in the rate of degradation.
When solutions of nifedipine were made in methanol and
kept in colored glassware in a refrigerator there was no
detectable degradation for at least one week.
C. SOLUBILITY STUDIES
The results of the solubility studies are shown in
table IV. It is clear that the solubility of nifedipine in
water at 25 degrees Celcius is extremely low (about 5 mg/L).
Further the solubility is not affected significantly (P >
0.05)

in the pH range of 1 to 7.4.

These results are in

accordance with the results obtained by Boje et al (10) who
(

reported a solubility of 5 - 6 micrograms per ml over pH 2.2
- 10.0 at 25 degrees.
With lN hydrochoric acid or O.lN sodium hydroxide as
the solvent the absorbance values were highly unstable.
Hence solubility determinations could not be made with these
solvents.
The solubilities of the two coprecipitates were higher
than the solubility of nifedipine. Especially the coprecipitate containing polyvinyl pyrrolidone (40T)

as the polymer

exhibited a four - fold increase in solubility over nifedipine.
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Tab1e IV.

Solubility of nifedipine and its coprecipitates
at 25 degrees Celcius.

Physical Form

crystalline
-do-

Absorbancea
(238 nm)

Solvent

Solubilitya
(mg/l)

water

0.304 -+ 0.027

5.01 -+ 0.44

phos . ( 7 • 4) b

0.259 -+ 0.026

4.26 -+ 0.43

0.359 -+ 0.047

5.91 -+ 0.77

-do-

O.lN HCl

-do-

l.ON HCl

-- c

-- c

-do-

O.lN NaOH

c

-- c

peg coppt

water

0.535 -+ 0.024

8.82 + 0.39

pvp coppt

water

1. 364

22.47 -+ 1. 54

-+ 0.036

(

amean

±

standard deviation (n

=

3).

bPhosphate buffer (O.OlM) pH 7 .4.
ccould not be determined because of rapid change in absorbanee.
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D. EVALUATION OF THE PHYSICAL CHARACTERISTICS OF THE TABLETS
The physical characteristics of tablets can affect the
release rate of drug. Also parameters such as weight variation and friability must lie within an acceptable limit for
the tablets to be acceptable. Therefore it was necessary to
evaluate the physical characteristics of each batch of tablets Tl through T6. Table V shows the results obtained from
these studies.
All the batches pass the official weight variation test
as described (USP XXI) for this weight category (+10% variation is acceptable for tablets weighing 130 mg or less).
Similarly, the friability was extremely low for each
batch of tablets although hardness was low for batches T3

(

and T4. In general, the maximum hardness imparted to the
tablets decreased with increasing proportion of PVP coprecipitate. With 100 mg PVP per tablet the tablets produced were
too soft to withstand any sort of handling and were therefore not taken for study.
On adding Accurel the hardness of T3 tablets increasd
as expected. With 5 and 7.5 mg Accurel per tablet (T5 and T6
respectively) added in the formulation of T3 tablets the
hardness increasd significantly (P < 0.01).

However the

difference between the hardness in tablets of batches T5 and
T6 was not significant.
Addition of Accurel also prolonged the disintegration
time of T3 tablets significantly (P < 0.01) and here again
the difference between T5 and T6 tablets was not signif icant.
56
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Tab1e V.

Physical characteristics of tablets.

PARAMETER
wt.

Var.
(mg)

Friability Disint. Time
(%)
(min)

Hardness
(kg)

Tl

100-106

0.1

6.5+0.5

3.6+0.2

T2

107-111

0.1

12.8+1.8

3.6+0.4

T3

104-110

0.0

11. 7+0. 8

1. 8+0. 2

T4

106-112

0.0

14. 2+1. 0

1. 6+0 .1

TS

106-116

0.0

19.3+0.5

2.4+0.2

T6

112-113

0.0

19.3+1.0

2.6+0.1

(
aRange of weights, n = 10.
bFor 10 tablets.
cMean + Standard Deviation, n = 6.
dMean + Standard Deviation, n = 5.
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E. DISSOLUTION STUDIES

(

Tables VI through IX and figure 8 show the results
obtained from the dissolution studies under non - sink conditions.

In these studies 20 mg equivalent of nifedipine

was taken in 1 liter of water at 37 degrees Celcius. From
the results it is clear that the dissolution rate of the
pure drug is extremely low. On the other hand the release
rate of nifedipine from the commercially available Adalat
soft - gelatin capsule is extremely high and plateau concentrations are reached between 10 and 20 minutes.
Among the test tablets the dissolution rate increased
in the order Tl < T2 < T3 < T4,

i.e.,

in the order of

increasing fraction of PVP coprecipitate. With all of the

(

tablets the dissolution rate

was much higher than that of

pure nifedipine powder. In the latter case only about 2 mg
of the drug dissolved in 2.5 hours. The low dissolution rate
was expected due to the poor solubility of nifedipine in the
crystalline form which is about 11.5 mg/L of water at 37
degrees (96,98). The enhanced release of nifedipine from the
four tablets is probably due to the presence of nifedipine
in the amorphous form in the two coprecipitates. Although
the exact physical nature of these dispersed systems was not
investigated it is believed that reduction of particle size
of the drug to the molecular and / or colloidal level is the
primary contributing factor for this striking phenomenon
(98) .
The increase in dissolution rate cannot be ascribed to
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Tab1e VI. Dissolution of Adalat capsulesa.

Concb
(mg/L)

Peak Areab

Time
(min)
10

44.5 -+ 0.60

17.8 -+ 0.24

20

45.9 -+ 0.50

18.3 -+ 0.20

30

46.8 -+ 0.48

18.7 -+ 0.19

45

46.9 + 0.38

18.7 -+ 0.15

60

47.8 -+ 0.37

19.1 -+ 0.15

90

47.32 -+ 0.32

18.9 -+ 0.13

120

47.35 -+ 0.20

18.9 -+ 0.08

360

47.60 -+ 0.35

19.0 -+ 0.14

(

aTwo capsules (equivalent to 20 mg of nifedipine) per liter
of water.

The standard curve was plotted using the equa-

tion :
Y

=

4.17X + 0.65

(r = 0.9998)

The dilution factor for the samples was 5/3.
bMean

±

standard deviation, n

(
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Tab1e VII. Dissolution of nifedipine powdera.

Peak Heightb
(cm)

Time
(min)

Conch
(mg/L)

10

2.5

0.26

20

4.2

0.44

30

5.7

0.59

60

9.1

0.95

90

12.8

1.33

120

15.7

1. 63

150

20.0

2.08

(
a2 O mg of powder/ liter of water. Standard curve was drawn
(dilution factor of samples was 5/3) using the equation:
Y

=

9.629X + 0.586

(r

=

bMean of 2 readings.

(
60

0.9914).

(
Tab1e VIII. Dissolution of tabletsa Tl and T2 under non sink conditionsb.

------- Tl
Time
(min)

(

------------

Absorbancec
(238nm)

Concc
(mg/L)

------------T2-----------Absorbancec
(238nm)

Con cc
(mg/L)

10

0.139+0.005

3.82+0.14

0.223+0.009

6.13+0.25

20

0.185+0.006

5.08+0.16

0.309+0.007

8.48+0.18

30

0.214+0.004

5.88+0.ll

0.323+0.005

8.86+0.14

45

0.240+0.003

6.59+0.07

0.340+0.003

9.34+0.07

60

0.259+0.002

7.12+0.06

0.350+0.009

9.60+0.25

90

0.283+0.006

7.76+0.16

0.354+0.005

9.72+0.14

120

0.298+0.004

8.17+0.11

0.366+0.008

10.04+0.22

180

0.320+0.003

8.78+0.07

0.376+0.007

10.32+0.18

480

0.358+0.006

9.83+0.16

0.388+0.003

10.66+0.07

18hr

0.371+0.002

10.18+0.06

0.388+0.003

10.66+0.07

asee Table I page 40 for composition of tablets.
bone tablet (equivalent to 20 mg nifedipine) per liter of
water.
cMean + Standard Deviation (n = 3) of diluted samples (dilution

factor = 5/3).

(
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Table IX. Dissolution of tabletsa T3 and T4 under non - sink
conditionsb.

------------ T3

---------

----------- T4

-----------

Time
(min)

Absorbancec
(238nm)

Concc
(mg/L)

Absorbancec
(238nm)

Concc
(mg/L)

10

0.256+0.007

7.03+0.18

0.275+0.007

7.54+0.18

20

0.378+0.002

10.39+0.0

0.396+0.007

10.87+0.18

30

0.384+0.004

10.55+0.11

0.438+0.008

12.03+0.21

45

0.390+0.006

10.70+0.16

0.441+0.008

12.10+0.21

60

0.397+0.006

10.91+0.16

0.445+0.005

12.21+0.14

90

0.392+0.002

10.75+0.06

0.443+0.005

12.17+0.14

120

0.398+0.003

10.93+0.07

0.442+0.001

12.14+0.03

180

0.398+0.002

10.93+0.06

0.440+0.002

12.09+0.06

480

0.414+0.005

11. 37+0 .14

0.443+0.005

12.17+0.14

aFor composition of tablets T3 and T4 see table I page 40.
bone tablet (equivalent to 20 mg of nifedipine) per liter of
water.
cMean + Standard deviation (n = 3) of diluted samples (dilution

factor

=

5/3).
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Fig. 8. Dissolution profiles of formulations under non - sink conditions.
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increase in the solubility of nifedipine since the solubility at 37 degrees was not measured. Although an increase was
found in the solubility of nifedipine in the coprecipitate
systems at 25 degrees other authors have reported only a
slight increase of the drug in aqueous solutions of PVP
(96,98) at 37 degrees. Since the saturation concentrations
achieved from the tablets (fig. 8) are in the range of the
reported solubility of nifedipine (about 11 mg/L)

in water

at 37 degrees this argument is convincing.
A higher dissolution rate with higher PVP fraction can
be explained by the observations of Sumnu (98) who found
that in solid disperse systems of nifedipine in PVP (in the
ratios 1:3 and 1:9)

(

the drug stayed essentially in the

amorphous state with no signs of crystallinity. On the other
hand nifedipine - PEG coprecipitates,

in the same ratios of

drug and polymer, indicated presence of crystallinity.
Other factors that could account for this phenomemon
are reduced surface tension on the drug particles (73),
formation of soluble complexes with the polymer (33,34), and
its dispersion form (11).
Previous studies on the dissolution behaviour of nifedipine coprecipitates have found that in these systems the
concentration of nifedipine in the solution increases rapidly in the beginning, forming a supersaturated solution, and
then decreases after half an hour due to crystallization of
the drug (96,98). We did not observe any decrease in concen-

(

trations possibly due to the smaller amount of drug taken
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per liter of the dissolution medium. In the reported studies
50 mg equivalent of nifedipine was taken in 500 ml of the
medium while we used only 20 mg equivalent of the drug in lL
of water.
Tables X through XIII compare the results of dissolution of the tablets obtained from the UV and HPLC assays.
The HPLC assay was performed on one sample per time point in
the dissolution profile of each tablet. Therefore the concentrations obtained from the HPLC are compared with the
corresponding concentrations obtained with the UV assay for
each case. For this reason the concentrations in column 3 in
the tables X through XIII are slightly different from the
concentrations in column 3 and 5 in tables VIII and IX which

(

are the means of 3 samples.
The difference in the results obtained by the two assay
methods is negligible - about 2% for the four taken together. Since the UV assay was less cumbersome, more reproducible and much faster it was used for further dissolution
studies.
Tables XIV and XV and figure 9 show the dissolution
profiles of all the six tablets in "near sink" conditions.
Sink conditions are approximated when the volume of the
dissolution medium is five to ten times the saturation
volume of the medium (38). Since in our studies a fraction
of the tablet equivalent to about 4 mg of nifedipine was
taken,

and since the solubility of nifedipine has been

reported to be about 11 to 12 mg/L at 37 degrees (also seen

65

Table

X.

Comparison

of

UV and HPLC

assay

results

for

dissolution of tablet Tl.

Time
(min)
10

(

Absorb
(238 nm)
0.148H4

Peak Areaa

Cone
(mg/L)

Cone
(mg/L)

Differ

(%)

3.95

9.08

3.80

3.70

20

0.188

5.16

13.01

5.45

-

5.61

30

0.218

5.98

14.54

6.09

-

1.84

45

0.243

6.67

16.30

6.83

-

2.36

60

0.261

7.17

17.33

7.26

-

1. 24

90

0.280

7.69

18.85

7.89

-

2.67

120

0.301

8.26

19.71

8.26

0.00

180

0.320

8.79

20.84

8.73

0.69

480

0.357

9.80

23.32

9.77

0.33

18 hr

0.369

10.13

23.91

10.02

1. 09

----------------------------------------------------------- o. 78
-----------------------------------------------------------

Mean

aThe standard curve was drawn using the equation:

Y = 3.979 X + 0.207

(r = 0.9999)

Dilution factor of samples

(
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5/3.
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Table XI. Comparison of UV and HPLC assay results for dissolution of tablet T2.

Time
(min)

Absorb
(238 nm)

Cone
(mg/L)

Peak Areaa

Cone
(mg/L)

Differ
(%)

10

0. 218

5. 9 8

13. 5 3

5.67

5. 2 3

20

0.302

8.29

19.39

8.12

2.03

30

0.318

8.73

20.84

8.73

0.00

45

0.337

9.25

21.91

9.18

0.76

60

0.360

9.88

23.26

9.74

1. 39

90

0.356

9.77

23.27

9.75

0.24

120

0.370

10.16

23.71

9.93

2.25

180

0.377

10.35

24.38

10.21

1.33

480

0.390

10.71

24.67

10.33

3.52

18 hr

0.394

10.82

24.76

10.37

4.15

----------------------------------------------------------2.09
-----------------------------------------------------------

Mean

astandard curve same as for Tl
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Table XII. Comparison of UV and HPLC assay results for
dissolution of tablet T3.

(

Time
(min)

Absorb
(238 nm)

10

0.251

6.89

20

0.380

30

Peak Areaa

Cone
(mg/L)

Cone
(mg/L)

Differ

16.28

6.47

6.09

10.43

24.39

9.70

6.99

0.384

10.55

25.98

10.33

2.08

45

0.391

10.73

26.60

10.58

1.40

60

0.390

10.71

25.94

10.32

3.64

90

0.390

10.71

26.36

10.48

2.15

120

0.401

11. 01

26.97

10.73

2.54

180

0.400

10.98

27.12

10.79

1. 73

480

0.415

11. 39

27.85

11. 08

2.72

(%)

-----------------------------------------------------------3.26
------------------------------------------------------------

Mean

astandard curve was drawn using the equation

y

=

4.191

x +

0.044

(r = 0.9999)

Dilution factor of samples = 5/3.

(
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Table XIII. Comparison of UV and HPLC assay results for
dissolution of tablet T4.

Peak Areaa

Time
(min)

Absorb
(238 nm)

Cone
(mg/L)

Cone
(mg/L)

Dif f er

10

0.271

7.44

17.24

6.85

7.94

20

0.389

10.68

25.62

10.19

4.59

30

0.430

11.86

28.76

11. 44

3.55

45

0.432

11.86

29.30

11. 65

1. 77

60

0.440

12.09

29.26

11. 64

3.72

90

0.438

12.03

29.47

11. 72

2.58

120

0.441

12.10

30.06

11. 95

1. 24

180

0.438

12.03

30.11

11. 97

0.50

480

0.442

12.14

29.53

11. 74

3.29

(%)

----------------------------------------------------------3.24
-----------------------------------------------------------

Mean

astandard curve same as for T3.
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Table XIV.

Dissolution of tablets Tl, T2 and T4 in "near
sink" conditions.

Percent released

Time
(min)
Tl

(

T2

T4

10

25.2 -+ 4.3

43. 7 + 0.9

65.2 -+ 0.4

20

31.5 + 0.2

55.2 + 1. 7

7 4. 6 -+ 1.4

30

3 6. 7 -+ 0.8

62 .4 + 2.8

8 0.1 -+ 5.3

45

4 7 .8 + 1.5

68.2 + 2.5

83.4 -+ 2.7

60

48. 9 -+ 1.5

74.6 + 3.6

85. 0 -+ 3.7

90

55. 6 + 1.3

77.1 + 0.9
-

89. 6 + 6.5
-

120

61.2 + 1.0
-

77 .5 -+ 0.8

92. 7 -+ 4.4

180

67.6 + 1.0

83.0 + 2.5
96.4 + 8.1

400
92.6 -+ 1.4

540
Tab wta

101.0 -+ 3.3

4.07

4.01

4.05

aweight (in mg) of fraction of tablet (equivalent of nifedipine)

taken in 1 liter of water.

(
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Tabl.e RXV.

Dissolution of tablets T3, TS, and T6 in "near
sink" condition.

Percent released

Time
(min)

(

T6

TS

T3

o.s

10

6S. 6 -+ 0.9

S3 .4 + 1.2

4 3.8 +

20

7 3. 6 -+ 3.S

6S.O + 3.0
-

S2. 2 + 1.S
-

30

7 6.S + 3.9

66.9 + 0.8

60. 2 + 1.8

4S

82. 3 -+ 2.7

74.8 +

o.s

67 .4 -+ 1.1

60

82.4 + 1.1
-

78.S + 0.6

7 2.4 -+ 0.8

90

87. 6 -+ 1.1

8S.1 + 2.S

77 .8 -+ 2.6

120

87. 7 -+ 1.8

88. 0 + 1.S
-

8S. s + 2.2
-

92. 7 -+ 1.S

87.6 -+ 3.1

98.4 -+ 1.9

94. 7 + 3.S

180
400

91.7 + 0.7

460
Tab w_t a

4.03

3.83

3.67

aweight (in mg) of fraction of tablet (equivalent of nifedipine) taken in 1 liter of water.

(
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from figure 8), the volume of 1 liter of water taken in our

(

studies was about 3 times the saturation volume. Hence it is
appropriate to say that sink conditions were -nearly achieved
in these studies.
From fig. 9 it can be seen that the dissolution rates
of tablets not containing Accurel polymer increase in the
order Tl < T2 < T3

=

T4. The dissolution rates of tablets T3

(containing 25% PEG coprecipitate and 75% PVP coprecipitate)
and T4 (containing 5% PEG coprecipitate and 95% PVP coprecipi tate) were not significantly different (P > 0.05) for 10,
20 and 30 minutes. For both of these tablets about 75% of
the drug was released in the first 20 minutes. It was then
decided to formulate a tablet which would release about 50%

(

of the drug in 20 minutes but no more than 90% in 3 hours.
For this we chose to modify the formulation of T3 using
Accurel polymer. our hypothesis was that addition of a small
amount of this hydrophobic polymer would reduce the dissolution rate and bring it to the desired level.
In the first case (tablet TS) 5 mg of Accurel was added
per tablet (total weight per tablet was 111 mg). As expected
the dissolution rate decreased but still about 65% of the
drug was released in 20 minutes and 93% was released in 3
hours.
In the second case (tablet T6) 7.5 mg of Accurel was
added per tablet and for this tablet about 52% of the drug
was released in 20 minutes and about 88% in 3 hours. Since
the dose of commercially available nifedipine capsules is 10
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(

to 20 mg tablet T6 would provide a suitable dosage regimen
if the in vivo release is similar to the in vitro results
obtained from our studies.
The convenience with which the release can be modified
from these tablets are encouraging although a zero order
release was not seen at the small fraction of the polymer
matrix. Further studies are needed with other proportions of
PEG or PVP and nifedipine and with formation of bilayer
tablets which would produce slower release from one half and
quicker release from the other. In this way a higher concentration of Accurel or other rate controlling matrix substance can be used which may give a better control of release
approaching zero - order.
Also,

in vivo studies need to be done in order to

better understand the relationship between the in
release and bioavailability.
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V. CONCIDSIONS

c
1.

The UV spectrophotometer at 238 nm was a sensitive,

reproducible and reliable assay method for the quantification of nifedipine for the dissolution studies. Stability
can be checked by the HPLC method which is also useful for
the decomposition studies.
2.

The photodegradation of nifedipine in solutions follows

first order kinetics with a t 90 of about 19 minutes in a
normally lighted room in the absence of daylight.
3.

In the pH range of 4.2 - 7.8 there is no appreciable

difference in the rate of photodegradation of nifedipine.
However, solutions kept in colored glassware and stored in a

(

refrigerator are quite stable for at least one week.
4. The solubility of nifedipine in water is about 5 mg/L at
25 degrees Celcius. The solubility in phosphate buffer (pH
7.4) and

0.1 N HCl was not significantly different from

that in water.
5. The tablets prepared with the various formulations had
acceptable weight variation and friability. However tablets
prepared with a high PVP fraction had low hardness.
6. Addition of 5% and 7.5% of Accurel increased the hardness
and disintegration time.
7. The dissolution rate of tablets increased in the order of
increasing fraction of PVP coprecipitate. Hence PVP is a
better material than PEG for the enhancement of dissolution
rate of nifedipine.

75

(

8. Accurel effectively retards the release of nifedipine
from the homogeneously dispersed monolithic tablet. However
the release rates at low Accurel concentrations do not
exhibit zero - order or the square root of time pattern.

(

l
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